514 related articles for article (PubMed ID: 29186355)
1. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
2. Topological integration of RPPA proteomic data with multi-omics data for survival prediction in breast cancer via pathway activity inference.
Kim TR; Jeong HH; Sohn KA
BMC Med Genomics; 2019 Jul; 12(Suppl 5):94. PubMed ID: 31296204
[TBL] [Abstract][Full Text] [Related]
3. Proteomic Approaches for Biomarker Panels in Cancer.
Tanase C; Albulescu R; Neagu M
J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
[TBL] [Abstract][Full Text] [Related]
4. Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies.
Nikolova O; Moser R; Kemp C; Gönen M; Margolin AA
Bioinformatics; 2017 May; 33(9):1362-1369. PubMed ID: 28082455
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
6. LinkedOmics: analyzing multi-omics data within and across 32 cancer types.
Vasaikar SV; Straub P; Wang J; Zhang B
Nucleic Acids Res; 2018 Jan; 46(D1):D956-D963. PubMed ID: 29136207
[TBL] [Abstract][Full Text] [Related]
7. The molecular make-up of a tumour: proteomics in cancer research.
Kolch W; Mischak H; Pitt AR
Clin Sci (Lond); 2005 May; 108(5):369-83. PubMed ID: 15831087
[TBL] [Abstract][Full Text] [Related]
8. Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression.
Ammad-Ud-Din M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2017 Jul; 33(14):i359-i368. PubMed ID: 28881998
[TBL] [Abstract][Full Text] [Related]
9. Feature set optimization in biomarker discovery from genome-scale data.
Fortino V; Scala G; Greco D
Bioinformatics; 2020 Jun; 36(11):3393-3400. PubMed ID: 32119073
[TBL] [Abstract][Full Text] [Related]
10. DeepCDR: a hybrid graph convolutional network for predicting cancer drug response.
Liu Q; Hu Z; Jiang R; Zhou M
Bioinformatics; 2020 Dec; 36(Suppl_2):i911-i918. PubMed ID: 33381841
[TBL] [Abstract][Full Text] [Related]
11. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data.
Xu Y; Dong Q; Li F; Xu Y; Hu C; Wang J; Shang D; Zheng X; Yang H; Zhang C; Shao M; Meng M; Xiong Z; Li X; Zhang Y
J Transl Med; 2019 Aug; 17(1):255. PubMed ID: 31387579
[TBL] [Abstract][Full Text] [Related]
12. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
14. RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines.
Basu A; Mitra R; Liu H; Schreiber SL; Clemons PA
Bioinformatics; 2018 Oct; 34(19):3332-3339. PubMed ID: 29688307
[TBL] [Abstract][Full Text] [Related]
15. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.
Lu Y; Ling S; Hegde AM; Byers LA; Coombes K; Mills GB; Akbani R
Semin Oncol; 2016 Aug; 43(4):476-83. PubMed ID: 27663479
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies.
Byron A; Bernhardt S; Ouine B; Cartier A; Macleod KG; Carragher NO; Sibut V; Korf U; Serrels B; de Koning L
Sci Rep; 2020 Dec; 10(1):21985. PubMed ID: 33319783
[TBL] [Abstract][Full Text] [Related]
17. Global MS-Based Proteomics Drug Profiling.
Carvalho AS; Matthiesen R
Methods Mol Biol; 2016; 1449():469-79. PubMed ID: 27613057
[TBL] [Abstract][Full Text] [Related]
18. Qupe--a Rich Internet Application to take a step forward in the analysis of mass spectrometry-based quantitative proteomics experiments.
Albaum SP; Neuweger H; Fränzel B; Lange S; Mertens D; Trötschel C; Wolters D; Kalinowski J; Nattkemper TW; Goesmann A
Bioinformatics; 2009 Dec; 25(23):3128-34. PubMed ID: 19808875
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
